Patents Assigned to Accentia Biopharmaceuticals, Inc.
-
Patent number: 9279803Abstract: The present invention provides methods of identifying subjects that are suitable and not suitable for high-dose cyclophosphamide treatment.Type: GrantFiled: September 22, 2011Date of Patent: March 8, 2016Assignees: The Johns Hopkins University, Accentia Biopharmaceuticals, Inc.Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, Jr., Susan Bonitz, Adam Kaplin, Carlos Santos
-
Patent number: 9026372Abstract: The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration.Type: GrantFiled: May 27, 2010Date of Patent: May 5, 2015Assignee: Accentia Biopharmaceuticals, Inc.Inventors: Francis O'Donnell, Jr., Carlos Santos
-
Patent number: 8673321Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, an autologous idiotypic vaccine and monoclonal antibodies that selectively bind B-cell specific antigens.Type: GrantFiled: September 12, 2011Date of Patent: March 18, 2014Assignees: The Johns Hopkins University, Accentia Biopharmaceuticals, Inc.Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, Jr., Susan Bonitz, Carlos Santos
-
Publication number: 20120237618Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.Type: ApplicationFiled: June 1, 2012Publication date: September 20, 2012Applicant: ACCENTIA BIOPHARMACEUTICALS, INC.Inventors: FRANCIS E. O'DONNELL, JR., ANGELOS M. STERGIOU
-
Patent number: 8211460Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.Type: GrantFiled: August 3, 2009Date of Patent: July 3, 2012Assignee: Accentia Biopharmaceuticals, Inc.Inventors: Francis E. O'Donnell, Jr., Angelos M. Stergiou
-
Publication number: 20120148577Abstract: A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.Type: ApplicationFiled: October 13, 2011Publication date: June 14, 2012Applicants: ACCENTIA BIOPHARMACEUTICALS, INC., JOHNS HOPKINS UNIVERSITYInventors: EPHRAIM J. FUCHS, LEO LUZNIK, ROBERT A. BRODSKY, RICHARD J. JONES, FRANCIS E. O'DONNELL, JR., CARLOS SANTOS, SUSAN BONITZ
-
Publication number: 20120148611Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, an autologous idiotypic vaccine and monoclonal antibodies that selectively bind B-cell specific antigens.Type: ApplicationFiled: September 12, 2011Publication date: June 14, 2012Applicants: Accentia Biopharmaceuticals, inc., The Johns Hopkins UniversityInventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, JR., Susan Bonitz, Carlos Santos
-
Publication number: 20120128685Abstract: The present invention relates to methods of treating an autoimmune disorder, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.Type: ApplicationFiled: September 22, 2011Publication date: May 24, 2012Applicants: Accentia Biopharmaceuticals, inc., The Johns Hopkins UniversityInventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, JR., Susan Bonitz, Carlos Santos, Adam Kaplin
-
Publication number: 20120129206Abstract: The present invention provides methods of identifying subjects that are suitable for high-dose cyclophosphamide treatment.Type: ApplicationFiled: September 22, 2011Publication date: May 24, 2012Applicants: Accentia Biopharmaceuticals, Inc., The Johns Hopkins UniversityInventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, JR., Susan Bonitz, Adam Kaplin, Carlos Santos
-
Publication number: 20120100162Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug, either alone, or in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.Type: ApplicationFiled: September 14, 2011Publication date: April 26, 2012Applicants: Accentia Biopharmaceuticals, Inc., The Johns Hopkins UniversityInventors: Robert A. Brodsky, Richard J. Jones, Richard F. Ambinder
-
Publication number: 20110117050Abstract: The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration.Type: ApplicationFiled: May 21, 2010Publication date: May 19, 2011Applicant: Accentia Biopharmaceuticals, Inc.Inventors: FRANCIS O'DONNELL, JR., Carlos Santos
-
Publication number: 20110097426Abstract: The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration.Type: ApplicationFiled: May 21, 2010Publication date: April 28, 2011Applicant: Accentia Biopharmaceuticals, Inc.Inventors: FRANCIS O'DONNELL, JR., Carlos Santos
-
Publication number: 20110082115Abstract: The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration.Type: ApplicationFiled: May 27, 2010Publication date: April 7, 2011Applicant: Accentia Biopharmaceuticals, Inc.Inventors: Francis O'Donnell, JR., Carlos Santos
-
Publication number: 20090297623Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.Type: ApplicationFiled: August 3, 2009Publication date: December 3, 2009Applicant: ACCENTIA BIOPHARMACEUTICALS, INCInventors: FRANCIS E. O'DONNELL, JR., ANGELOS M. STERGIOU
-
Publication number: 20090258000Abstract: The present invention is directed to compositions and methods for non-irritatively treating and preventing non-invasive fungus-induced mucositis. Specifically, the invention involves compositions including a mucosally non-irritative mixture of amphotericin B and a pharmaceutically acceptable carrier. Such compositions can be non-irritatively mucoadministered to prevent, reduce, or eliminate chronic non-invasive fungus-induced mucositis conditions.Type: ApplicationFiled: March 31, 2009Publication date: October 15, 2009Applicant: Accentia Biopharmaceuticals, Inc.Inventors: FRANCIS E. O'DONNELL, JR., Donald Deroo